Enrolment of patients initiated in North America and Europe in Episurf Medical’s IDE clinical trial
Episurf Medical (Nasdaq: EPIS B) today announces that the enrolment of patients has been initiated in the US and in Europe for the company’s IDE clinical trial for the Episealer® knee implant. The clinical trial, EPIC-Knee Episealer® Knee System IDE Clinical Study, is a prospective, randomised, controlled multi-centre study with two years’ follow-up of 180 subjects. The clinical trial is conducted at several clinics in the US, Canada, Germany, UK and Denmark. “We aim at being the world leader in our emerging orthopaedic niche, where today, a considerable amount of patients are left